© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
December 07, 2011
The FDA approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism following hip or knee replacements and for the prevention of stroke in patients with nonvalvular atrial fibrillation.